Overall, no significant association was found between CYP1A2*F polymorphism and colorectal cancer risk (dominant model: OR = 1.05, 95% CI = 0.94–1.18, Ph = 0.010, I2 = 54.1%; recessive model: OR = 1.01, 95% CI = 0.90–1.13, Ph = 0.426, I2 = 2.0%; homozygote model: OR = 1.04, 95% CI = 0.93–1.17, Ph = 0.144, I2 = 30.0%; heterozygote model: OR = 1.05, 95% CI = 0.94–1.17, Ph = 0.023, I2 = 49.2%; additive model: OR = 1.03, 95% CI = 0.95–1.11, Ph = 0.026, I2 = 48.2%, Fig. 2). The gene discussed is CYP1A2; the disease is colorectal cancer.